Loading...
•
Sep 30, 2021
Arrowhead Pharmaceuticals Q4 2021 Earnings Report
Announced fiscal year end results for 2021.
Key Takeaways
Arrowhead Pharmaceuticals reported its fiscal year end results, with a net loss of $140.85 million, or $1.36 per share.
Entered into an exclusive license agreement with GlaxoSmithKline (GSK) for ARO-HSD.
Presented new clinical data at The Liver Meeting for JNJ-73763989, ARO-HSD, and ARO-AAT.
Initiated and began dosing patients in AROAPOC3-2002 (MUIR) and AROANG3-2001 (ARCHES-2) Phase 2b clinical studies.
Received Breakthrough Therapy designation from the U.S. Food and Drug Administration for ARO-AAT.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...